An Escherichia coli carrier vaccine with surface-displayed protein MAP3061c elicits protective immunity against Mycobacterium paratuberculosis in mice. (December 2021)

• Record Type: Journal Article
• Authors: Xu, Qiu; Zhou, Wei; Ding, Shihao; Lu, Yao; Liu, Songyan; Cao, Jun; Zhang, Zhuo; Liu, Siguo; Yu, Shenye
• Is Part Of: Research in veterinary science. Volume 141(2021)
• Page Start: 180
• Page End: 189
• Publication Date: 2021-12
• Subjects: Mycobacterium avium subsp. paratuberculosis -- MAP3061c protein -- Surface display -- Carrier vaccine -- Immune protection; Veterinary medicine -- Periodicals; Veterinary Medicine -- Periodicals; Médecine vétérinaire -- Périodiques; Médecine vétérinaire -- Recherche -- Périodiques; Diergeneeskunde; 636.089
• DOI: 10.1016/j.rvsc.2021.10.019
• Languages: English
• ISSNs: 0034-5288

Abstract

Abstract: Johne's disease, or paratuberculosis, is a chronic granulomatous enteritis of ruminants caused by Mycobacterium avium subsp. paratuberculosis (MAP). This disease occurs worldwide and results in considerable economic losses in the livestock industry. There are no effective treatments for Johne's disease, so there is an urgent need to develop an efficient, economical, and stable vaccine for MAP control. Here, a live Escherichia coli ( E. coli ) surface display vaccine harboring the MAP3061c gene was developed through an ice nucleation protein (INP) surface display system. The experimental data demonstrated that MAP3061c has strong immunogenicity and that the surface displayed vaccine can stimulate mice to produce high levels of antibodies. Both CD4 + and CD8 + T cell counts as well as several cytokines – including IFN-γ, IL-4, IL-10, IL-17A and IL-23 – were significantly increased in the display vaccine group. Post-vaccination challenge with MAP in mice resulted in improved fitness of the mice as demonstrated by a lack of weight loss. Pathological results revealed that the surface display vaccine could reduce the degree of pathological damage and slowed the course of disease. Taken together, our data suggests that the E. coli carrier vaccine with surface-displayed MAP3061c elicits protective immunity against MAP, providing new insights into the development of a MAP vaccine. Highlights: A live E. coli surface display vaccine harboring the MAP3061c gene was developed through an INP surface display system. This surface display vaccine induced both a strong humoral immune response as well as a cell-mediated response in mice. This surface display vaccine could reduce the degree of pathological damage and slow the course of disease.